open access

Vol 17, No 6 (2012)
Original research articles
Published online: 2012-11-01
Submitted: 2011-12-13
Get Citation

A retrospective analysis of rectal and bladder dose for gynecological brachytherapy treatments with GZP6 HDR afterloading system

Mohammad Taghi Bahreyni Toossi, Mahdi Ghorbani, Yasha Makhdoumi, Mojtaba Taheri, Fatemeh Homaee Shandiz, Siavash Zahed Anaraki, Ali Soleimani Meigooni
DOI: 10.1016/j.rpor.2012.06.002
·
Rep Pract Oncol Radiother 2012;17(6):352-357.

open access

Vol 17, No 6 (2012)
Original research articles
Published online: 2012-11-01
Submitted: 2011-12-13

Abstract

Aim

The aim of this work is to evaluate rectal and bladder dose for the patients treated for gynecological cancers.

Background

The GZP6 high dose rate brachytherapy system has been recently introduced to a number of radiation therapy departments in Iran, for treatment of various tumor sites such as cervix and vagina.

Materials and methods

Our analysis was based on dose measurements for 40 insertions in 28 patients, treated by a GZP6 unit between June 2009 and November 2010. Treatments consisted of combined teletherapy and intracavitary brachytherapy. In vivo dosimetry was performed with TLD-400 chips and TLD-100 microcubes in the rectum and bladder.

Results

The average of maximum rectal and bladder dose values were found to be 7.62[[ce:hsp sp="0.25"/]]Gy (range 1.72–18.55[[ce:hsp sp="0.25"/]]Gy) and 5.17[[ce:hsp sp="0.25"/]]Gy (range 0.72–15.85[[ce:hsp sp="0.25"/]]Gy), respectively. It has been recommended by the ICRU that the maximum dose to the rectum and bladder in intracavitary treatment of vaginal or cervical cancer should be lower than 80% of the prescribed dose to point A in the Manchester system. In this study, of the total number of 40 insertions, maximum rectal dose in 29 insertions (72.5% of treatment sessions) and maximum bladder dose in 18 insertions (45% of treatments sessions) were higher than 80% of the prescribed dose to the point of dose prescription.

Conclusion

In vivo dosimetry for patients undergoing treatment by GZP6 brachytherapy system can be used for evaluation of the quality of brachytherapy treatments by this system. This information could be used as a base for developing the strategy for treatment of patients treated with GZP6 system.

Abstract

Aim

The aim of this work is to evaluate rectal and bladder dose for the patients treated for gynecological cancers.

Background

The GZP6 high dose rate brachytherapy system has been recently introduced to a number of radiation therapy departments in Iran, for treatment of various tumor sites such as cervix and vagina.

Materials and methods

Our analysis was based on dose measurements for 40 insertions in 28 patients, treated by a GZP6 unit between June 2009 and November 2010. Treatments consisted of combined teletherapy and intracavitary brachytherapy. In vivo dosimetry was performed with TLD-400 chips and TLD-100 microcubes in the rectum and bladder.

Results

The average of maximum rectal and bladder dose values were found to be 7.62[[ce:hsp sp="0.25"/]]Gy (range 1.72–18.55[[ce:hsp sp="0.25"/]]Gy) and 5.17[[ce:hsp sp="0.25"/]]Gy (range 0.72–15.85[[ce:hsp sp="0.25"/]]Gy), respectively. It has been recommended by the ICRU that the maximum dose to the rectum and bladder in intracavitary treatment of vaginal or cervical cancer should be lower than 80% of the prescribed dose to point A in the Manchester system. In this study, of the total number of 40 insertions, maximum rectal dose in 29 insertions (72.5% of treatment sessions) and maximum bladder dose in 18 insertions (45% of treatments sessions) were higher than 80% of the prescribed dose to the point of dose prescription.

Conclusion

In vivo dosimetry for patients undergoing treatment by GZP6 brachytherapy system can be used for evaluation of the quality of brachytherapy treatments by this system. This information could be used as a base for developing the strategy for treatment of patients treated with GZP6 system.

Get Citation

Keywords

Brachytherapy; Rectal dose; Bladder dose; GZP6 afterloading unit

About this article
Title

A retrospective analysis of rectal and bladder dose for gynecological brachytherapy treatments with GZP6 HDR afterloading system

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 17, No 6 (2012)

Pages

352-357

Published online

2012-11-01

DOI

10.1016/j.rpor.2012.06.002

Bibliographic record

Rep Pract Oncol Radiother 2012;17(6):352-357.

Keywords

Brachytherapy
Rectal dose
Bladder dose
GZP6 afterloading unit

Authors

Mohammad Taghi Bahreyni Toossi
Mahdi Ghorbani
Yasha Makhdoumi
Mojtaba Taheri
Fatemeh Homaee Shandiz
Siavash Zahed Anaraki
Ali Soleimani Meigooni

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl